AV
Ajay Verma
Twilight Bioscience, Formation Venture Engineering Foundry, Walter Reed National Military Medical Center, Johns Hopkins University Bloomberg School of Public Health, Yumanity Therapeutics
0000-0001-7715-0443
Employment
-
Twilight Bioscience CEO2023 - Present
-
Formation Venture Engineering Foundry General Partner2022 - Present
-
Yumanity Therapeutics EVP Head of R&D2021 - 2022
-
Codiak Biosciences Executive Vice President2019 - 2021
-
United Neuroscience Chief Medical Officer2017 - 2018
-
Biogen Inc VP2010 - 2016
-
Novartis Pharmaceuticals Corp VP2009 - 2010
-
Merck and Co Inc Director2006 - 2009
-
Uniformed Services University of the Health Sciences Faculty1995 - 2006
Education
-
Walter Reed National Military Medical Center Residency1991 - 1995
-
Johns Hopkins University Bloomberg School of Public Health PhD1989 - 1992
-
Johns Hopkins School of Medicine MD1984 - 1991
-
University of Maryland at College Park BS1980 - 1984
Projects & Funding
Projects & funding information is unavailable.
Publications (320)
- Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA), updates in 2022-2023. Cerebrovascular disease and the failure of elimination of Amyloid-β from the brain and retina with age and Alzheimer's dis… Save
- Differences in corneal nerve fiber density and fiber length in patients with painful chronic idiopathic axonal polyneuropathy and diabetic polyneuropathy Save
- EEG and ERP biosignatures of mild cognitive impairment for longitudinal monitoring of early cognitive decline in Alzheimer’s disease Save
- Correction: Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy (Alzheimer's Research & Therapy, (2020), 12, 1, (159), 10.1186/s13195-020-00727-x) Save
- Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study Save
- Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric $α$-synuclein accumulation in the brain and gut Save
- Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut Save
- Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis Save
- Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis Save
- Novel modification of Luminex assay for characterization of extracellular vesicle populations in biofluids Save